Published Date: 08 Jul 2024
Joseph Mikhael, MD, leads a discussion on the DREAMM-7 and DREAMM-8 trials
Read Full NewsBreast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether ...
The periodization of exercise training could give people undergoing cancer treatment and those in recovery a tailored pathway to support strength and resilience during the challenging journey of cancer care and rehabilitation.
A new clinical trial led by University of Alberta researchers is exploring whether heavy strength training is a safe and beneficial way to help combat the long-term physical challenges faced by head and neck cancer survivors.
1.
Which women need more than mammograms for breast cancer screening?
2.
No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.
3.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
4.
Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.
5.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
1.
Understanding Leiomyoma: Causes, Symptoms, and Treatment Options
2.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
3.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
4.
Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy
5.
Examining Serum Osmolality: What It Is And How To Test For It
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation